En Carta Diagnostics raised €5 million ($5.7 million) in private financing to advance regulatory clearances in the US and Europe and ramp manufacturing for its molecular testing products. The round includes €3 million in equity investment and €2 million in nondilutive funding from Bpifrance and others. The company’s platform combines aptamer-based target binding with loop-mediated isothermal amplification. En Carta previously received US FDA breakthrough device designation for its EC Pocket Lyme point-of-care test and also entered a codevelopment and commercialization agreement for a molecular sexually transmitted infection test with AAZ. Net proceeds are intended to speed commercialization of its Lyme test while supporting additional molecular assays, including continued work toward regulatory approval pathways in multiple regions.